AAAngel Ayuso-Sacido

Angel Ayuso-Sacido

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Angel Ayuso-Sacido has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • Noemí García-Romero

    Faculty of Experimental Sciences, Universidad Francisco de Vitoria, 28223 Madrid, Spain

    2 shared publications
  • Alvaro Monago-Sánchez

    Faculty of Experimental Sciences, Universidad Francisco de Vitoria, Madrid, Spain

    1 shared publication
  • Ana Hernández-Martínez

    Faculty of Experimental Sciences, Universidad Francisco de Vitoria, Madrid, Spain

    1 shared publication
  • Angel Pérez-Núñez

    Department of Neurosurgery, Hospital Universitario 12 de Octubre, Madrid, Spain

    1 shared publication
  • Antonio J. Sánchez-López

    Neuroimmunology Unit, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain

    1 shared publication
  • Beatriz Martín-Jouve

    Electron Microscopy Unit, Centro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain

    1 shared publication

Latest Publications

  • Open Access

    Glycosylated Delphinidins, Natural Antioxidants, Functionally Modulate the COX-2/PGE2 Axis and Downregulate MDR1 in Glioblastoma Cells

    by Constanza Cuevas, Yessica Nahuelpan, Darling Haro, Pamela Silva, Vicente Villagran, María A. Gleisner, Flavio Salazar-Onfray, Juan P. Muñoz, Christian Pávez, Noemi Garcia-Romero, et al.

    The multidrug resistance (MDR) phenotype, mediated by transporters such as MDR1/P-glycoprotein (P-gp), represents a critical obstacle in the treatment of glioblastoma (GB). Natural antioxidants such as glycosylated delphinidins—anthocyanins abundant in Chilean berries, particularly the native species Aristotelia chilensis (maqui)—have emerged as bioactive compounds that modulate inflammation and cancer-related pathways. In this context, the regulation of inflammation-associated signaling pathways, including COX-2 and NF-κB, represents a potential strategy to overcome chemoresistance. In this study, we evaluated the effect of delphinidin-3-glucoside (DEL-3) on the COX-2/PGE2 axis, MDR1 expression, and sensitivity to chemotherapeutic agents in U87-MG and GBM38 glioblastoma cells and in an NOD-SCID xenograft model using ELISA, RT-qPCR, Western blot, and luciferase reporter assays. DEL-3 reduced PGE2 production, consistent with functional modulation of the COX-2/PGE2 pathway, and downregulated MDR1 expression at both transcriptional and protein levels, in agreement with reduced promoter activity. Functionally, combined treatment with DEL-3 and MDR1-substrate chemotherapeutic agents enhanced cytotoxicity in U87-MG cells. Although DEL-3 did not significantly reduce tumor growth in a NOD-SCID xenograft model, MDR1 expression was reduced in treated tumors, indicating in vivo modulation of the target. Overall, these findings suggest that DEL-3, as a natural antioxidant, modulates inflammation-associated mechanisms and downregulates MDR1, thereby potentially enhancing the sensitivity of glioblastoma cells to MDR1-substrate chemotherapeutic agents.

  • Open Access

    Precision oncology in a dish: patient-derived glioma organoids to guide novel therapeutic strategies

    by Alvaro Monago-Sánchez, Laura Mateos-Madrigal, Josefa Carrión-Navarro, Ana Hernández-Martínez, Carlos Martínez-Riveiro, María Castelló-Pons, María Victoria Pacheco-Fuenmayor, Raquel Gutiérrez-González, Noemí Lomillos-Prieto, Ricardo Prat-Acín, et al.

    Gliomas are the most common primary brain tumors in adults and encompass a spectrum from IDH-mutant gliomas to highly aggressive IDH-wild type glioblastoma